Want to see CBUS full AI Analyst Report?
CBUS Stock Chart & Stats
$1.70
$0.04(2.65%)
At close: 4:00 PM EDT
$1.70
$0.04(2.65%)
Day’s Range― - ―
52-Week Range$1.09 - $4.19
Previous CloseN/A
Volume30.60K
Average Volume (3M)154.04K
Market Cap
$129.93M
Enterprise Value$370.99
Total Cash (Recent Filing)$20.43M
Total Debt (Recent Filing)$32.74M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding76,428,960
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside1370.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$8.17M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial TractionRevenue growth and initial sustainable-ingredient orders indicate early market acceptance. Further biofragrance scale-up could establish a recurring commercial stream and diversify Cibus beyond development-stage licensing.
Regulatory And Trait Platform ProgressFavorable regulatory determinations can shorten commercialization pathways and reduce approval uncertainty. A platform operating across multiple crops also supports a broader pipeline and creates opportunities to reuse development capabilities.
Cost Discipline And Lower DebtLower operating expenses and substantially reduced debt improve financial flexibility relative to prior periods. Continued cost control can extend development capacity while the company works toward larger commercial and royalty revenues.
Bears Say
Persistent Cash Burn And Short RunwayHeavy cash consumption means Cibus remains dependent on external financing or faster commercialization to sustain operations. The limited runway increases funding risk and could constrain investment in its trait pipeline.
Deep Losses And Thin EquityThe small revenue base does not yet cover development and corporate costs, leaving profitability distant. Deep losses and thin equity weaken balance-sheet resilience and make future capital needs more consequential for shareholders.
Partner-Dependent And Delayed CommercializationMaterial revenue opportunities depend on partners completing technical, production, pricing and ordering steps. Multi-year rice adoption and milestone timing delay cash-flow realization, increasing execution risk before the pipeline can support the business.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $4.19 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $129.93M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Aug 13, 2026. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.1.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.2.
How many shares outstanding does Cibus have?
Cibus has 76,428,960 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -6.842%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (1370.59% Upside)
$25.00 (1370.59% Upside)
Blogger Sentiment
Bullish
CBUS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.46%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CBUS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced mix of progress and remaining challenges. Positive developments include cost reductions, regulatory validations across multiple jurisdictions, initial commercial revenue from sustainable ingredients, tangible rice partnership expansions (Interoc and others), and an articulated path to larger royalty streams with a peak addressable rice royalty opportunity of over $200M. Counterbalancing these positives are a small current revenue base, a short cash runway (into early Q1 2027) with an increased net cash usage target (~$35M), sizable quarterly net losses, and multi-step, partner-dependent commercialization milestones that will stretch realization of royalties over multiple years. Given the combination of meaningful technical/regulatory progress and near-term financial constraints and execution risks, the overall tone is cautiously constructive but pragmatic.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$25.00
▲(1370.59% Upside)
Technical Analysis
Ownership Overview
25.62% Insiders
9.59% Mutual Funds
1.56% Other Institutional Investors
59.98% Public Companies and
Individual Investors